Clovis Oncology submits NDA for rucaparib to treat recurrent ovarian cancer

Clovis Oncology submits NDA for rucaparib to treat recurrent ovarian cancer

BOULDER -- Clovis Oncology (NASDAQ: CLVS) today announced it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for rucaparib as maintenance... Read More

Tuesday October 10, 2017 0 comments Tags: Boulder, Clovis Oncology, Rucaparib, Patrick J. Mahaffey, FDA

Clovis Oncology: Rucaparib improved survival in ovarian cancer patients

Clovis Oncology: Rucaparib improved survival in ovarian cancer patients

BOULDER -- ClovisOncology (NASDAQ: CLVS) today announced toplinedata from the confirmatory phase 3 ARIEL3 trial of rucaparib, which successfully achievedthe primary endpoint of improved... Read More

Monday June 19, 2017 0 comments Tags: Boulder, Clovis Oncology, Patrick Mahaffy, Rucaparib

Clovis Oncology offers stock to raise $175M

Clovis Oncology offers stock to raise $175M

BOULDER -- Clovis Oncology, Inc . (NASDAQ:CLVS) today announced it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $175... Read More

Tuesday January 3, 2017 0 comments Tags: Boulder, Clovis Oncology, Rubraca

Clovis announces FDA application for accelerated approval of cancer drug

Clovis announces FDA application for accelerated approval of cancer drug

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) announced the U.S. Food and Drug Administration (FDA) has accepted Clovis New Drug Application (NDA) for accelerated approval of rucaparib and... Read More

Thursday August 25, 2016 0 comments Tags: Boulder, Clovis Oncology, Rucaparib, Patrick J. Mahaffy, Foundation Medicine

Clovis Oncology initiates combined clinical trial of drugs to treat lung cancer

Clovis Oncology initiates combined clinical trial of drugs to treat lung cancer

BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) announced it has initiated a clinical trial to evaluate a novel combination therapy of Genentechs investigational cancer immunotherapy... Read More

Thursday January 28, 2016 0 comments Tags: Clovis Oncology, Patrick Mahaffy, Boulder, rociletinib

Clovis Oncology appoints Dale Hooks chief commercial officer

Clovis Oncology appoints Dale Hooks chief commercial officer

BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) announced Dale Hooks has been named senior vice president and chief commercial officer. Hooks succeeds Steve Hoerter , the companys current... Read More

Tuesday January 26, 2016 0 comments Tags: Clovis Oncology, Boulder, Dale Hooks, Steve Hoerter, Patrick Mahaffy

CBSA: 2015 was groundbreaking year for life sciences industry

CBSA: 2015 was groundbreaking year for life sciences industry

DENVER -- Colorados life sciences sector had a robust and groundbreaking 2015, according to the Colorado BioScience Association (CBSA), the states advocate for the industry. CBSA reported... Read More

Wednesday December 16, 2015 0 comments Tags: Denver, CBSA, April Giles, Medtronic, Covidien, Nivalis Therapeutics, Precision Biopsy, miRagen Therapeutics, Spectranetics, Surefire Medical, Cerapedics, dbMEDx, Clovis Oncology

Clovis Oncology raising $275M in public offering of common stock shares

Clovis Oncology raising $275M in public offering of common stock shares

BOULDER -- Clovis Oncology (Nasdaq: CLVS) announced it has commenced an underwritten public offering of common stock shares to raise approximately $275 million. Clovis said it intends to use... Read More

By: InnovatioNews Wednesday July 8, 2015 0 comments Tags: Boulder, Clovis Oncology